Table 1.

Clinical-pathological features and treatment of the MTC study group.

Sex
Male	6/8 (75%)
Female	2/8 (25%)
Age, mean	51 ± 14.5 years (range: 31–73)
Medullary thyroid cancer
Sporadic	8/8 (100%)
Hereditary	0
Extrahepatic metastases
Laterocervical and mediastinal lymphnodes	7/8 (87.5%)
Lung	3/8 (37.5%)
Bone	1/8 (12.5%)
Total hepatic tumor volume, mean	103 ± 183 mL (range: 12–551)
Administered dose, mean	235 ± 205 Gy (range: 90–677)
Treated liver lobe
Only right lobe1	4/8 (50%)
Bilobar (right and left lobe in two times)	3/8 (37.5%)
Bilobar (right and left lobe in one time)	1/8 (12.5%)
Previous treatment
Tyrosine kinase inhibitors	2/8 (25%)

¹In one of these patients, embolization (TAE) was performed at the level of the left lobe of the liver.